Page 6 - Lupin

ICICI Bank, TCS, Grasim: 5 F&O stocks with high PCR for your watchlist

F&O trading strategy: A high OI-based PCR suggests that traders were expecting limited downside at these counters, and were comfortable writing Puts.

Lupin and Huons partner to bring novel dry eye treatment to Mexico

Cyclosporine Ophthalmic Nanoemulsion is a preservative-free treatment for dry eye syndrome and healing corneal ulcers

Stocks to watch, July 16: Vedanta, HUL, Lupin, SpiceJet, Jio Fin Services

At 6:40 AM, GIFT Nifty futures traded steady at 24,620, indicating a subdued start for the markets.

Lupin divests women's health specialty biz in US to Evofem Biosciences

Company says divestment aligns US specialty business with therapeutic areas like respiratory, neurology

Stocks to watch, July 15: HCLTech, DMart, RVNL, IREDA, Zomato, Lupin

At 6:47 AM, GIFT Nifty futures indicated a major uptick of 91 points at 24,613, suggesting a gap-up start for the bourses

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook

Firm has a bunch of products lined up which will ensure limited earnings dip in FY27: Analysts

Lupin stock rallies 7%, hits multi-year high on healthy earnings outlook

The management expects to sustain US business at the $200 million plus level, going ahead with the continued ramp-up of Tiotropium and new product launches in fiscal year 2024-25.

Stocks to buy and sell on July 4: Bhel, Lupin, Firstsource Solutions

Pharma index has rebounded from the key support zone and LUPIN is offering fresh buying opportunity with favorable risk to reward

Stocks to watch on June 24: Sun Pharma, Cipla, Lupin, Vedanta, Tata Steel

Stocks to watch on June 24: USFDA has issued six observations for Cipla's Goa facility following an inspection from June 10 to June 21, 2024

Lupin appoints Abdelaziz Toumi as CEO of newly established subsidiary LMS

LMS will focus on the development, manufacture, and sale of Active Pharmaceutical Ingredients (APIs) while expanding into the Contract Development and Manufacturing Operations (CDMO) business

USFDA closes inspection of Lupin's facility with zero 483 observations

The inspection of the Nagpur facility was carried out by the US drug regulator from June 10 to June 13, 2024

Lupin recalls 51k bottles of generic drug due to defective containers in US

Drug firm Lupin is recalling over 51,000 bottles of a generic antibiotic medication in the US market due to a "defective container", according to the American health regulator. The US-based arm of the drug maker is recalling 51,006 bottles of Cefdinir for Oral Suspension (250 mg/5 mL) due to "defective container: lack of seal integrity," US Food and Drug Administration (USFDA) said in its latest Enforcement Report. Cefrine Oral Suspension is indicated for the treatment of a range of bacterial infections. The affected lot has been manufactured at Lupin's Mandideep-based plant and marketed in the US by Baltimore-based Lupin Pharmaceuticals, Inc, it said. The drug maker initiated the Class II nationwide (US) voluntary recall on May 8 this year. As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health

RIL, Sun Pharma, HDFC Bank, BHEL among 11 stocks to monitor on May 22

At 7:09 AM, GIFT Nifty futures indicated a modest uptick of 25 points, trading at 22,626 against Nifty futures

TCS, ONGC, SAIL, Ujjivan SFB, Trident among nine stocks to track on May 21

In the domestic market, foreign institutional investors (FIIs) offloaded shares worth Rs 92.95 crore, on May 18. Meanwhile, domestic institutional investors (DIIs) sold shares worth Rs 152.87 crore

Lupin appoints Jeffrey Kindler, Alfonso 'Chito' Zulueta as independent dirs

Pharma major Lupin Ltd on Thursday announced appointments of ex-Pfizer Chairman and CEO, Jeffrey Kindler and Alfonso 'Chito' Zulueta as independent directors on its board. Kindler is currently the CEO of Centrexion Therapeutics, a privately-held biotechnology company, Senior Advisor to Blackstone, Operating Partner at ARTIS Ventures and Global Chair of GLG Institute, Lupin said in a regulatory filing. He brings over four decades of business experience holding leadership positions at some of the world's most recognised companies, including Pfizer, where he served as Chairman & Chief Executive Officer, as well as McDonald's Corporation and General Electric Company, the company added. Before that, he was a partner at law firm Williams & Connolly. Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Ltd, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia, Lupin said. He is also President ..

Pharma major Lupin slides 5% as Q4 earnings miss street expectations

Mumbai-based Lupin posted a 52 percent year-on-year increase in consolidated net profit, reaching Rs 359.43 crore for the January-March quarter of FY24

IndiGo, Lupin, DCM Shriram and Gujarat Gas among six stocks to watch today

Stocks to Watch on May 7: Lupin Limited posted a 52 per cent year-on-year (Y-o-Y) surge in its consolidated net profit, reaching Rs 359.43 crore

Lupin Q4 result: Net profit up 52% at Rs 359 cr, revenue from ops rises 12%

'Our US sales remain healthy driven by inhalation products, and our India formulation business is delivering ahead of market,' said Nilesh Gupta, MDirector, Lupin

Q4FY24: Lupin, Godrej Consumer among 54 firms to report results on May 6

Q4 FY24 results today: Marico, Lupin, Gujarat Gas, Godrej Consumer Products, Indian Bank, Happiest Minds Technologies and Route Mobile will announce their fourth quarter and FY24 results on May 7